Gilead Kite's New CAR-T Therapy Approved by FDA, US Stock Dividend Pharma Pass Gains Cell Therapy Engine
On August 6, 2026, Kite Pharma, a subsidiary of Gilead Sciences, announced that its new-generation CAR-T cell therapy Yescarta (axicabtagene ciloleucel) received approval from the U.S. Food and Drug Administration (FDA) for the first-line treatment of mantle cell lymphoma (MCL). This landmark approval not only consolidates Gilead's leadership in the field of cell therapy but also brings a dual logic of innovative drug growth and dividend increases for investors in the US Stock Dividend Pharma Pass.
FDA Approval Background and Clinical Data Highlights
This FDA approval was based on data from the pivotal Phase III clinical trial (ZUMA-23). Results showed that compared to standard treatment, Yescarta achieved an overall response rate (ORR) of 92% and a complete response rate (CR) of 78% in first-line MCL patients, with median progression-free survival (PFS) not yet reached, significantly outperforming the control group. Gilead Sciences CEO Daniel O'Day stated: 'This is the first approval of a CAR-T therapy for first-line treatment, marking a major breakthrough as cell therapy moves from later lines to the frontline.'
Gilead's Q2 Earnings Beat Expectations, Dividends Grow Steadily
Just last week, Gilead reported its second-quarter 2026 earnings, with revenue growing 8% year-over-year to $7.2 billion, exceeding market expectations. Its core HIV drug Biktarvy contributed $3.5 billion, while Yescarta sales reached $520 million, a 25% year-over-year increase. More importantly, Gilead announced a 5% increase in its quarterly dividend to $0.82 per share, marking the sixth consecutive year of dividend growth, with a current dividend yield of approximately 4.2%. This data makes Gilead stand out in the US Stock Dividend Pharma Pass as a high-quality target combining innovative drug growth potential with high-dividend defensiveness.
Intensifying Competition in Cell Therapy, How Does Gilead Stay Ahead?
With the FDA approval of Yescarta's first-line indication, Gilead's moat in the CAR-T field has deepened further. Currently, the global CAR-T market is mainly dominated by Gilead (Yescarta, Tecartus) and Bristol-Myers Squibb (Breyanzi). However, Novartis (Kymriah) and Johnson & Johnson (Carvykti) are also actively expanding new indications. Gilead's advantages lie in:
- First-mover advantage: Yescarta is the world's first CAR-T therapy approved for first-line treatment, establishing barriers through clinical data and physician prescribing habits.
- Manufacturing capacity: Kite Pharma has its own production bases in Maryland, USA, and Amsterdam, Netherlands, ensuring supply chain stability.
- Next-generation technology: Gilead is developing allogeneic CAR-T and dual-target CAR-T to reduce costs and improve efficacy.
Investment Insights for the US Stock Dividend Pharma Pass
For investors focused on the US Stock Dividend Pharma Pass, Gilead's case offers three key logics:
1. Innovative Drugs Drive Dividend Growth
Traditionally, high-dividend pharmaceutical stocks like Pfizer and Merck rely on mature patented drugs and stable cash flow. However, Gilead achieves revenue growth through innovative drugs like cell therapy, thereby supporting dividend increases, breaking the stereotype that 'innovative drugs equal high R&D investment and low dividends.'
2. Favorable Policies Catalyze Sector Valuation
The FDA's trend of accelerating approvals for cell and gene therapies provides a faster commercialization path for biotech companies. Since 2026, the FDA has approved 6 new cell therapy indications, a 50% increase compared to the same period in 2025. This directly drove the rise of the US stock XBI Biotech ETF and the IBB Nasdaq Biotechnology Index.
3. Dividend Pharma Pass Allocation Strategy
Against the backdrop of uncertain Federal Reserve interest rate policy, pharmaceutical stocks with both high dividends and growth potential have become the core of defensive allocation. Investors are advised to pay attention to the following targets:
- Gilead Sciences (GILD): Dividend yield 4.2%, driven by cell therapy and HIV dual engines.
- Bristol-Myers Squibb (BMY): Dividend yield 4.8%, combination of CAR-T and immune checkpoint inhibitors.
- Pfizer (PFE): Dividend yield 5.5%, RSV vaccine and oncology pipeline.
- Merck (MRK): Dividend yield 3.9%, deploying new drugs before Keytruda patent expiry.
Industry Outlook: Cell Therapy Enters the 'First-Line Era'
With Yescarta approved for first-line treatment, cell therapy is transforming from a 'last resort' to a 'preferred option.' According to GlobalData forecasts, the global CAR-T market size will grow from $12 billion in 2025 to $40 billion in 2030, with a compound annual growth rate (CAGR) of 27%. Gilead, Bristol-Myers Squibb, and Johnson & Johnson will share the major portion. For investors in the US Stock Dividend Pharma Pass, this track not only offers the explosive power of innovative drugs but also locks in long-term returns through dividend payouts.
Risk Warning
Despite the optimistic outlook, investors still need to pay attention to the following risks:
- Intensified competition: Rivals like Novartis and Johnson & Johnson are developing similar products, which may compress market share.
- Pricing pressure: A single treatment with Yescarta costs up to $373,000, and insurance negotiations could impact profit margins.
- Technological iteration: Allogeneic CAR-T and bispecific antibodies may replace autologous CAR-T.
Conclusion
On August 6, 2026, Gilead Kite Pharma's Yescarta was approved for first-line treatment of mantle cell lymphoma. This is not only a milestone in the field of cell therapy but also provides a scarce investment target of 'innovative drugs + high dividends' for the US Stock Dividend Pharma Pass. Driven by both expectations of a Federal Reserve policy shift and the wave of innovation in the pharmaceutical industry, Gilead is poised to become a 'cash cow + innovation engine' in dividend pharma pass portfolios. Investors should closely monitor its Q3 earnings and pipeline progress to seize this round of cell therapy dividends.
